NDA 213793 · Rhythm
Imcivree
Setmelanotide Acetate · Subcutaneous · Melanocortin 4 Receptor Agonist
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Nov 25, 2020
Approved uses
4
Original approval plus efficacy supplements
Registered trials
26
10 Phase 3, 2 recruiting
FAERS reports
285
187 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 1, 2026.
IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged [ see Dosage and Administration (2.1) ]: 4 years and older with acquired hypothalamic obesity (HO) 2 years and older with syndromic or monogenic obesity due to: o Bardet-Biedl syndrome (BBS) o Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged (1): 4 years and older with acquired hypothalamic obsesity (HO). 2 years and older with Bardet-Biedl syndrome (BBS). 2 years and older with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by an genetic test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR-deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign. ( 1 ) Other types of obesity not related to acquired HO, BBS or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity. ( 1 ) 1.1 Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following...
Mechanism: Setmelanotide is an MC4 receptor agonist with 20-fold less activity at the melanocortin 3 (MC3) and melanocortin 1 (MC1) receptors. MC4 receptors in the brain are involved in regulation of hunger, satiety, and energy expenditure. Based on nonclinical evidence, setmelanotide may re establish MC4 receptor pathway activity to reduce food intake and promote weight loss through decreased caloric intake and increased energy expenditure in patients with obesity due to acquired HO, BBS, or POMC, PCSK1, or LEPR deficiency associated with insufficient activation of the MC4 receptor. The MC1 receptor is...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 19, 2026 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Dec 20, 2024 Supplement 7 · Efficacy · priority review OrphanLabelLetter
- Jun 16, 2022 Supplement 1 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Nov 25, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- IMCIVREE · SETMELANOTIDE ACETATE EQ 10MG BASE/ML (EQ 10MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Setmelanotide" as an intervention, any sponsor and status, largest first.
- EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayPivotal-lookingCompleted
Rhythm Pharmaceuticals, Inc.Industry
NCT05093634 · 296 participants · Start Apr 26, 2022 · Primary completion Dec 19, 2025
Drug: Setmelanotide; Placebo · For: Obesity; Genetic Obesity
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 66 sites in all
- Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityCompleted
Rhythm Pharmaceuticals, Inc.Industry
NCT03013543 · 213 participants · Start Feb 10, 2017 · Primary completion Mar 1, 2022
Drug: Setmelanotide · For: Genetic Obesity; Obesity; Obesity Due to Melanocortin 4 Receptor Deficiency
Sites: Birmingham, Alabama; Chandler, Arizona; Mesa, Arizona · 58 sites in all
- Long Term Extension Trial of SetmelanotidePivotal-lookingCompleted
Rhythm Pharmaceuticals, Inc.Industry
NCT03651765 · 205 participants · Start Jul 15, 2018 · Primary completion Jan 9, 2025
Drug: Setmelanotide · For: Obesity Associated With Defects in Leptin-melanocortin Pathway
Sites: Chandler, Arizona; Scottsdale, Arizona; San Diego, California · 27 sites in all
Tom HühneAcademic, hospital or other
NCT07674290 · 200 participants (planned) · Start Jan 1, 2023 · Primary completion Dec 31, 2030
Drug: Setmelanotide · For: Bardet Biedl Syndrome (BBS); Bardet Biedl Syndrome; Bardet-Biedl Syndrome (BBS) and 1 more
Sites: Essen, Germany
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayPivotal-lookingCompleted
Rhythm Pharmaceuticals, Inc.Industry
NCT04963231 · 164 participants · Start Nov 30, 2021 · Primary completion Aug 4, 2023
Drug: Setmelanotide; Placebo · For: Genetic Obesity
Sites: Scottsdale, Arizona; Suwanee, Georgia; Worcester, Massachusetts · 36 sites in all
- A Trial of Setmelanotide in Acquired Hypothalamic ObesityPivotal-lookingActive, not recruiting
Rhythm Pharmaceuticals, Inc.Industry
NCT05774756 · 143 participants · Start Apr 26, 2023 · Primary completion Mar 18, 2025
Drug: Setmelanotide; Placebo · For: Hypothalamic Obesity
Sites: Birmingham, Alabama; San Diego, California; Aurora, Colorado · 28 sites in all
Rhythm Pharmaceuticals, Inc.Industry
NCT02041195 · 99 participants · Start Jan 2014 · Primary completion Aug 2014
Drug: Setmelanotide; Placebo · For: Overweight and Obesity
Sites: Dallas, Texas; Madison, Wisconsin
Rhythm Pharmaceuticals, Inc.Industry
NCT05046132 · 77 participants · Start Aug 5, 2021 · Primary completion Apr 7, 2022
Drug: Setmelanotide; Moxifloxacin and 2 more · For: Healthy
Sites: Glendale, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea81
- off label use79
- skin hyperpigmentation64
- vomiting43
- headache42
- diarrhoea38
- fatigue36
- skin discolouration35
- decreased appetite27
- melanocytic naevus25
- weight increased25
- abdominal pain23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 22 |
| 2022 | 9 |
| 2023 | 32 |
| 2024 | 33 |
| 2025 | 133 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
Miller JL, van Santen HM, Phillips SA, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH, Dubern B, Mokrosinski J, et al. · Mol Metab 2017 · Clinical Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K, van den Akker E, Argente J, et al. · Lancet Diabetes Endocrinol 2020 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM, Chung WK, Dollfus H, et al. · Lancet Diabetes Endocrinol 2022 · Randomized Controlled Trial, Multicenter Study
- Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.
Roth CL, Scimia C, Shoemaker AH, et al. · Lancet Diabetes Endocrinol 2024 · Clinical Trial, Phase II, Multicenter Study
- Could setmelanotide be the game-changer for acquired hypothalamic obesity?
van Santen HM, Denzer C, Müller HL · Front Endocrinol (Lausanne) 2023 · Randomized Controlled Trial
Sponsor: Rhythm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.